Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on February 23, 2006. The filing serves as a voluntary update to risk factors disclosed in the company's Annual Report on Form 10-K for the fiscal year ended September 30, 2005. The report coincides with the filing of a Form S-4 registration statement regarding an exchange offer for the company's 5 5/8% Senior Notes due 2012 and 5 7/8% Senior Notes due 2015.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or debt figures for the reporting period. However, it references historical data from the fiscal year ended September 30, 2005:
- Gross Profit Margins: Declined from 5.42% in fiscal 2001 to 3.96% in fiscal 2005 due to competitive pressures.
- Customer Concentration: The top ten customers represented approximately 31% of operating revenue; the largest single customer accounted for 7.5%.
- GPO Relationships: Approximately 13% of operating revenue was derived from the three largest Group Purchasing Organizations (Novation, United Drugs, and Premier Purchasing Partners).
- Accounts Receivable: As of September 30, 2005, the largest trade receivable from a single customer represented approximately 13% of net accounts receivable.
- Segment Revenue: Purchases by United Drugs members represented approximately 4% of operating revenue. Approximately 11% of PharMerica's operating revenue was derived from Long-Term Care's contract with Beverly Enterprises, Inc.
Material Changes and Business Model Transition
The company is undergoing a significant transition in its Pharmaceutical Distribution segment's business model:
- Shift to Fee-for-Service: Moving away from a model dependent on manufacturer price increases and inventory holding toward a fee-for-service model. As of December 31, 2005, fee-for-service agreements were signed with a substantial majority of large branded pharmaceutical manufacturers.
- Margin Expectations: The company expects that during fiscal 2006, more than 75% of brand name manufacturer gross margin will not be contingent on manufacturer price increases.
- Contract Termination: In October 2005, the company received notice of termination of its GPO contract with United Drugs, effective mid-December 2005. The company expects to retain a substantial majority of United Drugs' members as direct customers.
- Facility Consolidation: An integration plan is underway to reduce distribution facilities from 51 to 28 by the end of fiscal 2006. As of December 31, 2005, 26 facilities had been closed and five new facilities were operational.
Outlook, Risks, and Contingencies
Management highlights several material risks that could adversely affect future operations and profitability:
- Regulatory Changes: Implementation of Medicare Part D (beginning 2006) and the Deficit Reduction Act of 2005 (DRA) may reduce reimbursement rates and eliminate manufacturer rebates for the Long-Term Care business. The DRA is projected to reduce net Medicare and Medicaid spending by approximately $11 billion over five years.
- Competitive Pressures: Intense competition from national wholesalers (e.g., Cardinal Health, McKesson) and direct manufacturer distribution continues to erode gross profit margins.
- Customer and Supplier Credit Risk: The bankruptcy or insolvency of significant customers or suppliers could materially affect results, particularly given the concentration of receivables and payables.
- Integration and IT Risks: Risks associated with the consolidation of the distribution network and the outsourcing of significant IT activities to IBM, effective July 1, 2005.
- Internal Controls: The company is preparing for the Section 404 Sarbanes-Oxley Act requirements for the fiscal year ending September 30, 2006, with no assurance that internal controls will be deemed effective.
Investor Verification Checklist
- Verify the actual retention rate of United Drugs members following the GPO contract termination.
- Monitor the impact of the fee-for-service business model transition on gross margins in fiscal 2006.
- Assess the financial impact of Medicare Part D implementation and DRA provisions on the Long-Term Care segment.
- Review the progress and cost efficiency of the distribution network consolidation (targeting 28 facilities by end of fiscal 2006).
- Confirm the status of the renewal of the Beverly Enterprises, Inc. contract, which expires mid-fiscal 2006.